Clinical Trials Logo

Hemophilia B, Congenital clinical trials

View clinical trials related to Hemophilia B, Congenital.

Filter by:
  • None
  • Page 1

NCT ID: NCT02796222 Completed - Clinical trials for Hemophilia A, Congenital

Factor Product Utilization and Health Outcomes in Patients With Hemophilia

Start date: April 2016
Phase:
Study type: Observational

Recombinant factor VIII Fc (rFVIIIFc) and recombinant factor IX Fc (rFIXFc) are extended half-life coagulation factors approved by Health Canada in 2014 for the treatment of severe hemophilia A and B, respectively. The objectives of this observational study is to describe the change in annual factor consumption, clinical and patient-reported outcomes for patients who switch from recombinant factor VIII (rFVIII) and recombinant factor IX (rFIX) to rFVIIIFc/ rFIXFc in Canada, and to explore clinicians' and patients' reasons for switching or not switching.